Loading...
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
Hoskin, P Sartor, O O'Sullivan, J Johannessen, D Helle, S Logue, John P Bottomley, D Nilsson, S Vogelzang, N Fang, F
Hoskin, P
Sartor, O
O'Sullivan, J
Johannessen, D
Helle, S
Logue, John P
Bottomley, D
Nilsson, S
Vogelzang, N
Fang, F
Citations
Altmetric:
Abstract
Primary results from the phase 3 ALSYMPCA trial showed that radium-223 dichloride (radium-223), a targeted α-emitter, improved overall survival compared with placebo and was well tolerated in patients with castration-resistant prostate cancer and symptomatic bone metastases. We did a prespecified subgroup analysis from ALSYMPCA to assess the effect of previous docetaxel use on the efficacy and safety of radium-223.
Description
Date
2014-11
Publisher
Collections
Keywords
Type
Article
Citation
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. 2014, 15 (12):1397-406 Lancet Oncol